Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Candid, a startup, is investing $370 million to prove the worth of bispecifics in autoimmune diseases. Summit's lung cancer drug has shown significant benefits over Keytruda, a popular immunotherapy drug. Relay's breast cancer drug also showed promise in early trials. Biotech IPOs are crucial in the industry, and their performance is being closely monitored. Early study data on Terns, a potential contender in the obesity drug market, is also discussed.Summit Therapeutics has declared victory over Keytruda in advanced non-small cell lung cancer, with their drug Ivonescimab showing a 49% higher effectiveness in reducing disease progression or death in a late-stage study. GSK is set to approach the FDA with positive Phase III data for a long-acting asthma medication. Terns Pharmaceuticals' investigational GLP-1 pill has shown promising weight loss results. Sino Biological has launched a new center for bioprocessing, and various pharmaceutical companies are making advancements in their pipelines. The FDA tracker highlights Travere's full approval for an IgAN drug.The challenges faced in the cell and gene therapy industry as it grows in popularity among investors and innovators are discussed. Shortages of brand-name diabetes and obesity medications from Novo Nordisk and Eli Lilly, such as Ozempic and Mounjaro, are due to high demand. Efforts are being made to ramp up manufacturing and develop new medications. Lilly recently made a billion-dollar deal with Haya Therapeutics to develop genetic obesity medications. The revival of drugs for Huntington's disease after initial trial failures is mentioned. Challenges in turning new drugs into successful assets even after FDA approval are highlighted, along with a poll on which presidential candidate would support policies favorable to the pharma industry. Information on staying compliant with the EU GMP Annex 1 revision is also provided.